FDA Approves Orca Bio’s Tregzi, Ushering In a First-of-Its-Kind Cell Therapy for Transplant Patients
The FDA has cleared Orca Bio’s allogeneic T cell–based immunotherapy, Tregzi, to reduce graft-versus-host disease (GVHD) in patients undergoing treatment for blood cancers. Notably, Orca Bio says Tregzi marks the first-ever approval of a cell therapy built on regulatory T cells — a milestone that reshapes what’s possible in allogeneic transplant.
A Defining First for Orca Bio
Beyond the science, this approval carries real weight for the company itself. Tregzi is Orca Bio’s first approved therapy, and the California-based biotech argues it validates its “high-precision platform and the potential of its pipeline.” (Orca Bio remains privately held and does not trade publicly, though the approval has already fueled speculation about a potential IPO.)
CEO and co-founder Nate Fernhoff framed the moment in sweeping terms. “Today’s approval marks a defining moment for Orca Bio and for the future of allogeneic transplant, which has long offered curative potential, but also carries significant risks like graft versus host disease,” he told BioSpace. Moreover, Fernhoff explained that the therapy pairs hematopoietic stem and progenitor cells (HSPCs) to rebuild the immune system with highly purified regulatory T cells (Tregs) to suppress GVHD — an approach designed to “build on the foundation of transplant” by applying precision science to how it’s manufactured and delivered.
Why GVHD Matters
To understand the significance, consider the problem Tregzi targets. GVHD is a severe complication that can strike after a stem cell or bone marrow transplant, occurring when donor immune cells attack the recipient’s body and trigger inflammation and tissue damage.
The FDA underscored just how stubborn that risk has been. “For patients with blood cancers who need stem cell transplantation, chronic graft-versus-host disease has long been one of the most feared and difficult-to-prevent complications,” said Karim Mikhail, acting director of the FDA’s Center for Biologics Evaluation and Research. He added that the approval “offers a genuine new approach” and “reflects the promise of what cellular therapy can deliver for patients.”
The Data Behind the Approval
Crucially, the greenlight rests on strong Phase 3 evidence. Orca’s Precision-T study enrolled 187 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and mixed-phenotype acute leukemia. Researchers randomly assigned them to receive either Tregzi plus single-agent tacrolimus or a conventional allogeneic hematopoietic stem cell transplant plus tacrolimus and methotrexate.
The results favored Tregzi across the board. Specifically, 78% of Tregzi patients achieved chronic GVHD-free survival, compared with just 38.4% of those who underwent a standard transplant. In addition, GVHD-free and relapse-free survival more than doubled for the Tregzi group, while overall survival reached 94% versus 83% for the conventional approach. Just as importantly, the safety profile held up well, with side effects the FDA described as generally consistent with what patients undergoing stem cell transplantation would expect.
What Comes Next
Ultimately, the medical community sees this as more than a single product win. Robert Negrin, professor of medicine in blood and marrow transplantation at Stanford Medicine, called Tregzi’s approval “a defining moment for the transplant community.” As a result, the therapy not only expands options for high-risk blood cancer patients but also strengthens the case for Treg-based cell therapies more broadly — and puts a spotlight on the rest of Orca Bio’s pipeline.
